Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 18/20 | 0.60 |
| ▸ | BRAF | P15056 | 8/20 | 0.59 |
| ▸ | BCL6 | P41182 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309668 | 0.87 | TNNI3K (0.61) | TNNI3KBRAFEGFR | |
| SCHEMBL4128544 | 0.84 | JAK1 (0.63) | TNNI3KBRAFEGFRSYK | |
| SCHEMBL4001783 | 0.79 | JAK3 (0.61) | TNNI3KBRAFEGFRSYK | |
| SCHEMBL27631427 | 0.77 | SYK (0.74) | BRAFBCL6SYK | |
| SCHEMBL19482711 | 0.76 | CDK2 (0.52) | TNNI3KEGFRSYK | |
| SCHEMBL9986007 | 0.75 | TNNI3K (0.60) | TNNI3KBRAFEGFR | |
| SCHEMBL301265 | 0.74 | JAK1 (0.60) | TNNI3KBRAFEGFRSYK | |
| SCHEMBL4005818 | 0.74 | JAK3 (0.71) | SYK | |
| SCHEMBL30763999 | 0.74 | BRD4 (0.52) | TNNI3KSYK | |
| SCHEMBL29176792 | 0.74 | BRD4 (0.52) | TNNI3KSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | TNNI3K 218/4885BRAF 226/4885BCL6 194/4885 |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | TNNI3K 218/4885BRAF 226/4885BCL6 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.